As development of molecular biomarkers hastens, administrators, clinicians and regulators are working to organize and define biomarkers’ appropriate roles in clinical care—and discussing how to efficiently share the massive amounts of genomic data that will result.
Biomarkers, if used appropriately, could ensure patients receive the appropriate treatment sooner, and that they have better outcomes at reduced costs. But despite the potential and expanding capabilities, barriers to full-fledged use remain.
Total global spending on oncology medicines – including therapeutic treatments and supportive care – reached the $100 billion threshold in 2014, while spending on oncology drugs in the U.S. increased 5.3 percent compounded annual growth rate (CAGR) in 2014 to reach $42.4 billion, according to a new report.
In a large, mutli-center study, researchers discovered potential biomarkers for accurately assessing idiopathic pulmonary fibrosis (IPF) disease progression.
The study, published in the March 11 issue of The Lancet Respiratory Medicine, was led by R. Gisli Jenkins, PhD, with the Division of Respiratory Medicine at the University of Nottingham in the United Kingdom. The PROFILE study was funded by GlaxoSmithKline R & D and the Medical Research Council.